Evidence map›Paper›PMID 40814635›Full record

ArticleKidney international reports2025

Association of Phenylacetylglutamine and Cognitive Impairment in CKD.

Hélène Levassort, Julie Boucquemont, Sophie Liabeuf, Solène M Laville, Céline Lange, Luc Frimat, Christian Combe, Denis Fouque, Maurice Laville, Christian Jacquelinet and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Hélène LevassortGeriatric Department, University Medical Department 1, AP-HP, Ambroise Paré Hospital, University Hospital Group Pais Saclay, Boulogne-Billancourt, France.
Julie BoucquemontClinical Epidemiology Team, Centre for Research in Epidemiology and Population Health, Paris-Saclay University, Inserm U1018, Versailles Saint-Quentin University, Villejuif, France.
Sophie LiabeufPharmacoepidemiology Unit, Department of Clinical Pharmacology, Amiens-Picardie University Medical Center, FAmiens, France.
Solène M LavillePharmacoepidemiology Unit, Department of Clinical Pharmacology, Amiens-Picardie University Medical Center, FAmiens, France.
Céline LangeClinical Epidemiology Team, Centre for Research in Epidemiology and Population Health, Paris-Saclay University, Inserm U1018, Versailles Saint-Quentin University, Villejuif, France.
Luc FrimatNephrology Department, University Regional Hospital of Nancy, Vandoeuvre-lès-Nancy, France.
Christian CombeBordeaux University, INSERM, Bordeaux Public Health, Bordeaux, France.
Denis FouqueService de Néphrologie, Centre Hospitalier Lyon Sud, Université de Lyon, Carmen, Pierre-Bénite, France.
Maurice LavilleCarmen INSERM U1060, Université Claude Bernard Lyon 1, Pierre-Bénite, France.
Christian JacquelinetClinical Epidemiology Team, Centre for Research in Epidemiology and Population Health, Paris-Saclay University, Inserm U1018, Versailles Saint-Quentin University, Villejuif, France.
Yves-Edouard HerpeBiobanque de Picardie, Biological Resource Center of the Amiens University Hospital, Amiens, France.
Islam Amine LarabiDepartment of Pharmacology and Toxicology, Raymond Poincaré Hospital, AP-HP, Garches, France.
Jean-Claude AlvarezDepartment of Pharmacology and Toxicology, Raymond Poincaré Hospital, AP-HP, Garches, France.
Natalia Alencar de PinhoClinical Epidemiology Team, Centre for Research in Epidemiology and Population Health, Paris-Saclay University, Inserm U1018, Versailles Saint-Quentin University, Villejuif, France.
Marion PépinGeriatric Department, University Medical Department 1, AP-HP, Ambroise Paré Hospital, University Hospital Group Pais Saclay, Boulogne-Billancourt, France.
Ziad A MassyClinical Epidemiology Team, Centre for Research in Epidemiology and Population Health, Paris-Saclay University, Inserm U1018, Versailles Saint-Quentin University, Villejuif, France.
CKD-REIN Study Collaborators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Chronic kidney disease (CKD) leads to the accumulation of uremic toxins (UTs). Studies have suggested that UTs are associated with cognitive impairment (CI) in patients with CKD. Recently, studies reported that phenylacetylglutamine (PAG) contributes to the association between CKD and CI. However, this association has not been investigated in nondialysis-dependent adults with CKD. Methods: The CKD-Renal Epidemiology and Information Network (CKD-REIN) cohort study included 3033 patients with CKD stages 2 to 5. This cross-sectional analysis included those with a PAG measurement and a mini-mental state examination (MMSE) score within 3 months of each other. CI was defined as an MMSE score ≤ 26 out of 30. Logistic regression was used to assess the association between PAG and CI. Results: Of the 2590 patients included (mean [SD] age: 67 [13] years, mean [SD] estimated glomerular filtration rate [eGFR]: 34 [13] ml/min per 1.73 m Conclusion: This study shows that a higher serum PAG level was associated with CI in nondialysis-dependent adults with CKD and highlight a new UT associated with CI in patients with CKD. Further studies are needed to confirm the causal nature of the association and to explore strategies for reducing serum PAG levels to protect cognition.

Indexed as

chronic kidney diseasecognitionphenylacetylglutamineuremic toxins

Identifiers

PMID40814635
PMCPMC12348181

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.